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45.2%), or antidepressants. However, younger children were more likely than older 
children to receive antipsychotics (65.7% versus 53.1%) and stimulants (45.0% versus 
29.9%). Between 2005 and 2007, psychotropic medication use changed within 
the younger age group, with anticonvulsant use decreasing by nearly 10% and 
stimulant use increasing by 7%. CONCLUSIONS: Psychotropic medication use is 
prevalent in both younger and older children with bipolar spectrum disorders. 
Younger children are signiﬁcantly more likely to receive antipsychotics and stimulants 
as compared with older children, and less likely to receive lithium, anticonvulsants, 
or antidepressants.
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OBJECTIVES: To evaluate the national trends in prescribing antidepressants for 
depression before and after the FDA advisory regarding the risk of suicidality for 
pediatric patients in 2003. METHODS: Visit-based data 1996–2007 from the 
National Ambulatory Medical Care Survey and the National Hospital Ambulatory 
Medical Care Survey were analyzed. Data were analyzed among children aged 5–17 
years. For comparison, we also analyzed data from adults. We reported the number 
of visits (ofﬁce-based and outpatient combined) with a diagnosis of depression and 
number of visits and proportion with antidepressants prescribed for each two-year 
period. Robust 95% conﬁdence intervals (CI) were calculated and the results were 
weighted to reﬂect national estimates. RESULTS: Among children, the number of 
depression visits increased steadily during the pre-advisory period from 1996–1997 
(2.4 million; 95% CI: 1.8–3.1) to 2002–2003 (4.4 million; 3.3–5.5), and decreased 
by 16% in 2004–2005 (3.7 million; 2.8–4.5) and 27% in 2006–2007 (3.2. million; 
2.3–4.1) compared with the level in 2002–2003 following the advisory. The number 
of visits with any antidepressant prescribed increased two-fold from 1996–1997 (1.3 
million; 0.9–1.7) to 2002–2003 (2.9 millions; 2.3–3.6), and decreased by 28% in 
2006–2007 (2.1 millions; 1.5–2.6). The proportion of depression visits with any 
antidepressant prescribed increased from 1996–1997 (54%; 42%–67%) to 2002–
2003 (66%; 59%–74%), and remained stable in 2004–2005 (65%; 56%–74%) and 
2006–2007 (64%; 55%–72%) after the advisory. Among adults, the increase in trends 
was not interrupted by the advisory. Proportion of use for ﬂuoxetine continued to 
increase after the advisory, while the increasing trend reversed after the advisory for 
non-ﬂuoxetine SSRIs among children. CONCLUSIONS: There was a downward trend 
in ambulatory utilization of antidepressants prescribed for depression among children 
after the FDA advisory, coincided with a decrease in visits with a diagnosis of depres-
sion. There appeared to be a switch in utilization from non-ﬂuoxetine SSRIs to 
ﬂuoxetine.
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OBJECTIVES: To examine the association of patient characteristics including age, 
sex, race, geographic diversity, income status, insurance type, perceived mental health 
status, perceived health status, and co-morbidities of depression with the use of phar-
macotherapy, psychotherapy and combined treatment for depression. METHODS: 
Depressed individuals in the age group 18–65 were identiﬁed from the Medical 
Expenditure Panel Survey 1998–2006. Pregnant women and individuals with other 
mental health illnesses were excluded. Individuals with at least four antidepressant 
prescriptions yearly without any psychotherapy formed the pharmacotherapy group. 
Individuals with at least four psychotherapy visits yearly and no antidepressants 
formed the psychotherapy group. Combined therapy group included individuals with 
at least four psychotherapy visits and four antidepressants yearly. Survey weights were 
applied to get national estimates. RESULTS: There were estimated 1,115,091 patients 
in the combined group, 3,173,122 in the pharmacotherapy group and 733,264 in the 
psychotherapy group. Patients in the group 46–65 years were 88% (p = 0.000) more 
likely to get pharmacotherapy than combined therapy, and 45% (p = 0.007) less likely 
to get psychotherapy compared to patients in the age group 18–30. Patients not living 
in a Metropolitan Statistical Area (MSA) were 80% (p < 0.000) more likely to receive 
pharmacotherapy than combined therapy, compared to patients living in MSA. 
Patients other than white and black have 85% (p = 0.040) higher likelihood of receiv-
ing psychotherapy than the combined therapy compared with whites. Patients with 
self-reported fair or poor physical health were 70% (p = 0.002) less likely to receive 
psychotherapy than combined therapy, compared to those reporting excellent health. 
Self-reported poor mental health predicts higher likelihood of receiving combined 
therapy than pharmacotherapy or psychotherapy alone (p < 0.000). CONCLUSIONS: 
There are signiﬁcant differences among the three treatment groups based on their 
demographic characteristics. Age, region, perceived overall health status and perceived 
mental health status were signiﬁcant predictors of treatment received by the patients.
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OBJECTIVES: To describe 10-year trends in patient, physician and prescribed medica-
tions during outpatient visits for pediatric attention-deﬁcit/hyperactivity disorder 
(ADHD) METHODS: We identiﬁed all visits in children (3–18) with ADHD (ICD-9 
314.00/314.01) from 1998–2007 utilizing two national probability samples: the 
National Ambulatory Medical Care Survey and the National Hospital Ambulatory 
Medical Care Survey. We excluded pre/post surgery visits for a ﬁnal sample of 584,276 
visits and then weighted these visits to be representative of the US (using SUDAAN 
software) before calculating frequencies to characterize trends in patient and practice 
factors, as well as ADHD medication utilization. RESULTS: Visits for ADHD in 
children increased from 7.9 to 15.3 million (93%) from 1998–2007. Across all years, 
∼75% of visits were made by males. Visits were frequently made by white children 
(>80% in all years) with a trend of increasing visits by non-white children by 2006–
2007 (13.0% in 1998–1999 to 20.1% by 2006–2007). Visits among pediatricians rose 
from 38.3% in 1998–1999 to 48.4% in 2006–2007 with a decrease in specialist visits 
(from 43.1% to 33.7% of all visits). Across all years, mono-therapy was the predomi-
nant medication prescription (>60%), although ∼1/3rd of all visits did not note an 
ADHD medication. The use of methylphenidate mono-therapy dropped from 40.8% 
in 1998–1999 to 27.9% in 2006–2007. Dextroamphetamine mono-therapy rose from 
19.3% to 28.7% from 1998–1999 to 2002–2003, but then fell to 22.3% by 2006–
2007. The use of newer non-stimulant medications was apparent starting in 2002, but 
remained low (∼10%) across the rest of the interval. CONCLUSIONS: Visits made 
by children with ADHD increased over the decade, while use of medications for 
ADHD, particularly stimulants, decreased by 2006–2007 with no corresponding 
increase in the use of newer non-stimulant agents. New therapeutic options, changing 
guidelines, and emerging safety concerns make this an important area for ongoing 
research.
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OBJECTIVES: From a Canadian societal perspective, little is known about the impact 
of Attention Deﬁcit Hyperactivity Disorder (ADHD) in adults. A methodology for the 
design and conduct of a web-based survey used to populate a Canadian economic 
model is described. METHODS: An IRB approved, wed-based survey was adminis-
tered to evaluate the impact of ADHD in pre-identiﬁed Canadian subjects with this 
condition. There were 3 subgroups of interest: an ADHD group with self-reported 
controlled symptoms, an ADHD group with self-reported uncontrolled symptoms, and 
a non-ADHD reference group. Eligible participants received a 28-item questionnaire 
(English or French) which evaluated socio-demographic characteristics, ADHD treat-
ment, co-morbidities, health care resource utilization, functional status (Sheehan Dis-
ability Scale), productivity (Work Productivity Assessment and Activity Impairment; 
WPAI), and health-related quality of life (EQ-5D). Validation rules were pre-pro-
grammed to optimize data quality and survey completion at the point of data entry. 
EQ-5D utilities and productivity losses from WPAI were used to inform an economic 
model. Other data were used as supportive information. RESULTS: The targeted 
number of completed questionnaires, n = 174, was reached within 2 weeks of study 
launch after 1,878 survey invitations were circulated. More speciﬁcally, 69 controlled, 
70 uncontrolled and 35 non-ADHD subjects responded. Among participants, 56% 
were male, mean age was 35 years, 43% were diagnosed with ADHD in adulthood, 
and the majority responded in English. Functional status and utility values were sig-
niﬁcantly lower for subjects with uncontrolled versus controlled ADHD. Employment 
rates were lower (59% vs. 74%, p = 0.06), and overall work impairment was signiﬁ-
cantly higher for uncontrolled versus controlled ADHD subjects, respectively. CON-
CLUSIONS: Web-based surveys are a cost and time efﬁcient methodology for evidence 
gathering in support of economic evaluations. Despite some inherent limitations of 
online studies, such as generalizability, survey variables and outcomes can be tailored 
to collect data from populations and sub-groups of interest.
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OBJECTIVES: None of the published literature comparing outcomes measures 
between serotonin reuptake inhibitors (SSRIs) and sertonin-norepinephrine reuptake 
inhibitors (SNRIs) control for doctors’ practice and prescribing patterns due to the 
limitations of claims databases. We showed how to derive doctors’ practice and 
prescribing patterns for this group of patients from U.S. claims data. METHODS: 
